These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21113693)

  • 21. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
    Adler RA; Hastings FW; Petkov VI
    Osteoporos Int; 2010 Apr; 21(4):647-53. PubMed ID: 19533207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spotlight on denosumab in postmenopausal osteoporosis.
    Moen MD; Keam SJ
    BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoporosis in men: epidemiology and treatment with denosumab.
    Sidlauskas KM; Sutton EE; Biddle MA
    Clin Interv Aging; 2014; 9():593-601. PubMed ID: 24748777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab: What's new?
    Bogado CE; Zanchetta MB; Boailchuk JA; Massari FE; Zanchetta JR
    Curr Osteoporos Rep; 2011 Mar; 9(1):12-9. PubMed ID: 21132405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoporosis: non-hormonal treatment.
    Rizzoli R
    Climacteric; 2007 Oct; 10 Suppl 2():74-8. PubMed ID: 17882678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.
    Silverman SL
    Curr Osteoporos Rep; 2009 Sep; 7(3):91-5. PubMed ID: 19723467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on osteoporosis treatment.
    Nogués X; Martinez-Laguna D
    Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone complications of androgen deprivation therapy: screening, prevention, and treatment.
    Lattouf JB; Saad F
    Curr Opin Urol; 2010 May; 20(3):247-52. PubMed ID: 20224416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.